Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins

Human Gene Therapy

Volumn 23, Issue 5, 2012, Pages 484-491

  Ayala Breton, Camilo ^a   Barber, Glen N ^b   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; MEMBRANE ANTIGEN; PROSTATE MEMBRANE SPECIFIC ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCHEMISTRY; IN VIVO STUDY; MEASLES VIRUS; MOUSE; NONHUMAN; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ENVELOPE; VIRUS REPLICATION;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FOLATE RECEPTOR 1; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HEMAGGLUTININS, VIRAL; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MEASLES VIRUS; MICE; MICE, SCID; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; VESICULOVIRUS; VIRAL FUSION PROTEINS;

MEASLES VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84861690462     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.146     Document Type: Article

References (39)

1. Balachandran, S., and Barber, G.N. (2000). Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50, 135-138.
2. Balachandran, S., and Barber, G.N. (2004). Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5, 51-65. (Pubitemid 38121596)
3. Bergman, I., Whitaker-Dowling, P., Gao, Y., and Griffin, J.A. (2004). Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology 330, 24-33. (Pubitemid 39446564)
4. Bergman, I., Griffin, J.A., Gao, Y., and Whitaker-Dowling, P. (2007). Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to her2/neu. Int. J. Cancer 121, 425-430. (Pubitemid 46917713)
5. Chang, S.S., Reuter, V.E., Heston, W.D., et al. (1999). Five different anti-prostate-specific membrane antigen (psma) antibodies confirm psma expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198. (Pubitemid 29316022)
6. Clarke, D.K., Cooper, D., Egan, M.A., et al. (2006). Recombinant vesicular stomatitis virus as an hiv-1 vaccine vector. Springer Semin. Immunopathol. 28, 239-253. (Pubitemid 44764280)
7. Dingli, D., Peng, K.W., Harvey, M.E., et al. (2005). Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem. Biophys. Res. Commun. 337, 22-29. (Pubitemid 41393753)
8. Dö rig, R.E., Marcil, A., Chopra, A., and Richardson, C.D. (1993). The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295-305. (Pubitemid 23320293)
9. Edge, R.E., Falls, T.J., Brown, C.W., et al. (2008). A let-7 micro-RNA-sensitive vesicular stomatitis virus demonstrates tumorspecific replication. Mol. Ther. 16, 1437-1443.
10. Ekstrand, A.J., James, C.D., Cavenee, W.K., et al. (1991). Genes for epidermal growth factor receptor, transforming growth factor a, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51, 2164-2172.
11. Fisher, K.D., and Seymour, L.W. (2010). HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev. 62, 240-245.
12. Frecha, C., Costa, C., Negre, D., et al. (2008). Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112, 4843-4852.
13. Frecha, C., Levy, C., Cosset, F.L., and Verhoeyen, E. (2010). Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol. Ther. 18, 1748-1757.
14. Funke, S., Maisner, A., Muhlebach, M.D., et al. (2008). Targeted cell entry of lentiviral vectors. Mol. Ther. 16, 1427-1436.
15. Funke, S., Schneider, I.C., Glaser, S., et al. (2009). Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 16, 700-705.
16. Garcia-Sastre, A., and Biron, C.A. (2006). Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312, 879-882. (Pubitemid 43727313)
17. Hadac, E.M., Peng, K.W., Nakamura, T., and Russell, S.J. (2004). Reengineering paramyxovirus tropism. Virology 329, 217-225. (Pubitemid 39423972)
18. Hasegawa, K., Nakamura, T., Harvey, M., et al. (2006). The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin. Cancer Res. 12, 6170-6178. (Pubitemid 44703783)
19. Jenks, N., Myers, R., Greiner, S.M., et al. (2010). Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-b in rodents and nonhuman primates. Hum. Gene Ther. 21, 451-462.
20. Johnson, J.E., Nasar, F., Coleman, J.W., et al. (2007). Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360, 36-49.
21. Kelly, E.J., Nace, R., Barber, G.N., and Russell, S.J. (2010). Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J. Virol. 84, 1550-1562.
22. Lech, P.J., and Russell, S.J. (2010). Use of attenuated paramyxoviruses for cancer therapy. Expert Rev. Vaccines 9, 1275-1302.
23. Liu, C., Hasegawa, K., Russell, S.J., et al. (2009). Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69, 1128-1141.
24. Majid, A.M., Ezelle, H., Shah, S., and Barber, G.N. (2006). Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 80, 6993-7008. (Pubitemid 44025198)
25. Muik, A., Kneiske, I., Werbizki, M., et al. (2011). Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J. Virol. 85, 5679-5684.
26. Nakamura, T., Peng, K.W., Vongpunsawad, S., et al. (2004). Antibody-targeted cell fusion. Nat. Biotechnol. 22, 331-336. (Pubitemid 38295767)
27. Nakamura, T., Peng, K.W., Harvey, M., et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23, 209-214. (Pubitemid 40255331)
28. Obuchi, M., Fernandez, M., and Barber, G.N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843-8856. (Pubitemid 36936096)
29. Ong, H.T., Trejo, T.R., Pham, L.D., et al. (2009). Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther. 17, 1012-1021.
30. Paraskevakou, G., Allen, C., Nakamura, T., et al. (2007). Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRviii expressing gliomas. Mol. Ther. 15, 677-686. (Pubitemid 46431987)
31. Peng, K.W., Donovan, K.A., Schneider, U., et al. (2003). Oncolytic measles viruses displaying a single-chain antibody against cd38, a myeloma cell marker. Blood 101, 2557-2562. (Pubitemid 36857613)
32. Russell, S.J., and Peng, K.W. (2007). Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333. (Pubitemid 47016683)
33. Russell, S.J., and Peng, K.W. (2009). Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 330, 213-241.
34. Stojdl, D.F., Lichty, B.D., Tenoever, B.R., et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275. (Pubitemid 37329791)
35. Tatsuo, H., Okuma, K., Tanaka, K., et al. (2000a). Virus entry is a major determinant of cell tropism of Edmonston and wildtype strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins. J. Virol. 74, 4139-4145. (Pubitemid 30214419)
36. Tatsuo, H., Ono, N., Tanaka, K., and Yanagi, Y. (2000b). [the cellular receptor for measles virus: Slam (cdw 150)]. Uirusu 50, 289-296.
37. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., et al. (1997). Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 74, 193-198. (Pubitemid 27234510)
38. Vongpunsawad, S., Oezgun, N., Braun, W., and Cattaneo, R. (2004). Selectively receptor-blind measles viruses: identification of residues necessary for slam-or cd46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78, 302-313. (Pubitemid 37549743)
39. Wang, X., Yin, L., Rao, P., et al. (2007). Targeted treatment of prostate cancer. J. Cell. Biochem. 102, 571-579. (Pubitemid 47557412)